ACM
NVCR icon

ADAR1 Capital Management’s NovoCure NVCR Stock Holding History

ADAR1 Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,000
Closed -$440K – 329
2025
Q4 		$440K Hold
34,000
– – 0.03% 193
2025
Q3 		$439K Buy
+34,000
New +$454K 0.04% 144

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

ADAR1 Capital Management's NVCR Position: Q1 2026 in Review

ADAR1 Capital Management sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 34,000 shares — an estimated $440K sold.

ADAR1 Capital Management first reported a position in NVCR in Q3 2025 and held it in 2 quarters. The position peaked at $440K in Q4 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • ADAR1 Capital Management reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 34,000 NovoCure shares in Q1 2026, an estimated $440K.
  • ADAR1 Capital Management first reported a position in NovoCure in Q3 2025 and held it in 2 quarters.
  • ADAR1 Capital Management's NovoCure position peaked at $440K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.